The poster presentation at AAIC had some errors and this was exploited by the petition. We will discuss the errors at length on another post.
This post however is to inform readers that SavaDx or plasma p-tau end points were not part of the phase 2b trial and are not subject to the blinding requirements. Cassava independently chose to get their SavaDx test assay verified by correlating it with p-tau results from the commercial assay run by Quanterix. This was purely to show SavaDx as a valid biomarker while also showing how reduced altered FLNA helped with lowering p-tau181.
Any errors on the poster therefore should not impact phase 3 decisions by the FDA.